title: Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
abstract: Lansoprazole fast-disintegrating tablet (LFDT) is a new patient-friendly formulation of lansoprazole. Since lansoprazole is an antiulcer agent and is unstable under acidic conditions, we have developed LFDT as an orally disintegrating tablet containing enteric-coated microgranules. The effect of compression on dissolution behavior was investigated, as compression affected cleavage and crushing of the enteric layer. To decrease cleavage and crushing of the enteric layer, the effects of the combined ratio of methacrylic acid copolymer dispersion to ethyl acrylate-methyl methacrylate copolymer dispersion and the concentration of triethyl citrate on the dissolution in the acid stage and the dissolution in the buffer stage were evaluated. By adjusting the ratio of methacrylic acid copolymer dispersion to ethyl acrylate-methyl methacrylate copolymer dispersion to 9 : 1 and adding a 20% triethyl citrate concentration, sufficient flexibility of the enteric layer and sufficient stability against compression forces were achieved. Agglomeration of enteric-coated microgranules during the coating process was decreased at the optimized concentration of triethyl citrate and glyceryl monostearate. We compared the absorption properties of LFDT and lansoprazole capsules in dogs. The absorption profiles of LFDT were similar to those of lansoprazole capsules.
authors.affiliation: Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industries, Ltd. Shimizu_Toshihiro@takeda.co.jp
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Shimizu
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nakano
authors.forename: Shuji
authors.initials: S
authors.lastname: Morimoto
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Tabata
authors.forename: Naoru
authors.initials: N
authors.lastname: Hamaguchi
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Igari
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D002626:Chemistry, Pharmaceutical; D019245:Compressive Strength; D004285:Dogs; D007408:Intestinal Absorption / Q000502:physiology; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D012995:Solubility; D013608:Tablets, Enteric-Coated
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D013608:Tablets, Enteric-Coated; D064747:Lansoprazole; D009853:Omeprazole